SKYE NASDAQ
Skye Bioscience, Inc.
1W: +0.6%
1M: -8.7%
3M: +138.9%
YTD: +91.3%
1Y: -60.6%
3Y: -46.7%
5Y: -94.2%
$1.68
+0.08 (+5.00%)
Weekly Expected Move ±17.6%
$1
$1
$2
$2
$2
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
0
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$7.4M
52W Range1.5-39.92
Volume10,755
Avg Volume287,805
Beta2.90
Dividend—
Analyst Ratings
Company Info
CEOPunit Dhillon
Employees2
SectorHealthcare
IndustryBiotechnology
IPO Date2015-01-06
Websiteskyebioscience.com
11250 El Camino Real
San Diego, CA 92130
US
San Diego, CA 92130
US
858 410 0266
About Skye Bioscience, Inc.
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in San Diego, California.
Latest News
5Am Partners Vii, Llc Sells 33,892 Shares of Skye Bioscience (NASDAQ:SKYE) Stock
Andrew Schwab Sells 33,892 Shares of Skye Bioscience (NASDAQ:SKYE) Stock
Skye Bioscience (NASDAQ:SKYE) Trading 2.8% Higher – Time to Buy?
Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1
UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Schwab Andrew J. | S-Sale | 4,528 | $1.61 | 2026-09-23 |
| 5AM Partners VII, LL | S-Sale | 4,528 | $1.61 | 2026-09-23 |
| Schwab Andrew J. | S-Sale | 27,612 | $1.65 | 2026-09-22 |
| Schwab Andrew J. | S-Sale | 1,088 | $1.65 | 2026-09-22 |
| 5AM Partners VII, LL | S-Sale | 27,612 | $1.65 | 2026-09-22 |